Apremilast Therapy for Acute Gouty Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to learn about a possible new medicine, apremilast, for treating acute gout and compare how it works to indomethacin, a medication that has been used to treat gout for over 50 years.

In order to learn about apremilast, half the participants in this study will receive apremilast and half the participants in this study will receive indomethacin.

This study will measure the severity and duration of acute gout attacks in research participants, as well as measures of quality of life and any side effects or adverse reactions to the medication.

There will be three study visits: a screening/baseline visit on Day 1, a visit to evaluate response to treatment with study medication at Day 7, and a follow-up visit at Day 21.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

NCT00829829

Intercritical Gout

COMPLETED PHASE3

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

NCT03636373

Gout Attack

TERMINATED PHASE4

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

NCT04772313

Uncontrolled Gout

COMPLETED PHASE4

A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

NCT00142558

Acute Gout

COMPLETED PHASE4

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

NCT05253833

Gout Arthritis, Gouty Hyperuricemia +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

WITHDRAWN

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Gout

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

apremilast

Experimental treatment for acute gout

Group Type EXPERIMENTAL

apremilast

Intervention Type DRUG

apremilast 20 mg taken twice daily by mouth

indomethacin

Medication currently used for the treatment of acute gout

Group Type ACTIVE_COMPARATOR

indomethacin SR

Intervention Type DRUG

indomethacin SR 75 mg taken twice daily by mouth

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

apremilast

apremilast 20 mg taken twice daily by mouth

Intervention Type DRUG

indomethacin SR

indomethacin SR 75 mg taken twice daily by mouth

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must understand and voluntarily sign the informed consent
* Must have the diagnosis of gout proven by identification of urate crystals from body fluids
* Must be male age \>18 years at the time of consent
* Must be able to adhere to the study visit schedule and other protocol requirements
* Must meet the following laboratory criteria:

* Hemoglobin \> 9.0 g/dL
* White blood cell (WBC) count \> 3000/μL and \< 14,000/μL
* Platelet count \>100,000/μL
* Serum creatinine \< 2.0mg/dL
* Total bilirubin \< 2.0 mg/dL
* Aspartate transaminase (AST) and alanine transaminase (ALT) \<1.5 X upper limit of normal
* Males, including those who have had a vasectomy, must agree to use barrier contraception (latex condom) when engaging in sexual activity with a female of child-bearing potential (FCBP) while on study medications and for 84 days after taking the last does of the medication

Exclusion Criteria

* Inability to provide voluntary consent
* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he were to participate in the study or confounds the ability to interpret the data from the study
* Females
* Systemic fungal infection
* History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment in the past 2 years
* An active infection at presentation
* Use of any investigational medication within 4 weeks prior to start of study or 5 pharmacokinetic/pharmacodynamic half-lives, whichever is longer
* Any use of corticosteroids, cyclosporine, methotrexate, cyclophosphamide, azathioprine, mycophenolate within 4 weeks prior to start of study
* Any clinically significant abnormality on 12-lead ECG screening
* Malignancy or history of malignancy (except for treated and cured basal-cell skin carcinomas \> 3 years prior to screening)

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No